Lipika Goyal, MD | UniHealth

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

16 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Goyal’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

16 of 16 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Silicon (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health smartHMO (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health the ONE (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
SCAN Balance (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Classic (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN MyChoice (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Strive (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026

California Medical Board record

Licence C184275 · Current

Licensed to practise in California · since 2023 · expires 2027-02-28 · Harvard Medical School.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$27,761

Medicare paid this office $27,761 for 60 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Long return visit (40+ min)	20	$8,193	$130
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	23	$7,105	$97
Long return visit (40+ min)	16	$3,612	$172
New patient visit (60+ min)	12	$1,885	$157
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	19	$1,657	$28

See all 9 services

Sort by

Every Original Medicare service billed

Long return visit (40+ min)	20	$8,193	$130
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	23	$7,105	$97
Long return visit (40+ min)	16	$3,612	$172
New patient visit (60+ min)	12	$1,885	$157
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	19	$1,657	$28
Initial hospital care with moderate level of medical decision making at least 75 minutes	11	$1,565	$142
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	17	$596	$15
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	12	$415	$30
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	11	$194	$15

Who their Medicare patients are

60 Original Medicare patients in 2024. Average age 73 · Women 57% · Also on Medicaid 30% · Health risk score 3.08. Sicker patients than 9 in 10 peers; the typical medical oncology clinician is at 2.11.

Conditions among them: High blood pressure 75% · Coronary heart disease 42% · Diabetes 38% · Cancer 37% · Heart failure 30% · Chronic kidney disease 27% · Depression 25% · Atrial fibrillation 23%.

The office billed $109,312, Medicare allowed $35,728 and paid $27,761; for 329 services of 11 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	60	329	73	3.08	$109,312	$27,761
2023	16	52	72	1.32	$27,216	$5,506
2022	81	178	73	2.65	$90,207	$18,732
2021	129	364	72	2.52	$173,344	$42,069
2020	159	424	73	2.85	$171,658	$38,797
2019	174	428	71	2.52	$202,928	$40,471
2018	170	528	72	2.84	$244,794	$50,001
2017	175	589	72	2.71	$257,680	$55,651
2016	179	589	72	2.42	$251,381	$53,830
2015	145	546	71	2.40	$216,396	$47,853
2014	98	323	71	2.82	$119,083	$27,544
2013	38	116	70	2.06	$46,102	$10,652

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2022: 4 services

Sort by

Original Medicare services billed in 2022

Long return visit (40+ min)	45	$9,411	$121
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	12	$3,671	$87
Telephone medical discussion with physician, 21-30 minutes	27	$2,474	$77
Initial hospital care with moderate level of medical decision making at least 75 minutes	11	$2,375	$170

2021: 4 services

Sort by

Original Medicare services billed in 2021

Long return visit (40+ min)	89	$30,092	$125
Telephone medical discussion with physician, 21-30 minutes	34	$4,203	$84
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	14	$4,201	$89
Initial hospital care with moderate level of medical decision making at least 75 minutes	16	$2,947	$173

2020: 5 services

Sort by

Original Medicare services billed in 2020

Long return visit (40+ min)	109	$22,499	$95
Telephone medical discussion with physician, 21-30 minutes	59	$7,091	$70
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	16	$3,785	$95
Initial hospital care with moderate level of medical decision making at least 75 minutes	18	$3,247	$171
Return visit (30+ min)	12	$842	$70

2019: 4 services

Sort by

Original Medicare services billed in 2019

Long return visit (40+ min)	151	$31,277	$93
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	16	$3,126	$89
Extended office or other outpatient service, first hour	20	$2,660	$106
Initial hospital care with moderate level of medical decision making at least 75 minutes	13	$2,287	$176

2018: 3 services

Sort by

Original Medicare services billed in 2018

Long return visit (40+ min)	144	$38,447	$92
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	18	$5,635	$89
Initial hospital care with moderate level of medical decision making at least 75 minutes	20	$4,179	$174

2017: 4 services

Sort by

Original Medicare services billed in 2017

Long return visit (40+ min)	110	$33,883	$91
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	44	$12,186	$88
Initial hospital care with moderate level of medical decision making at least 75 minutes	40	$7,006	$167
Return visit (30+ min)	15	$1,099	$52

2016: 5 services

Sort by

Original Medicare services billed in 2016

Long return visit (40+ min)	126	$33,161	$89
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	32	$9,725	$85
Initial hospital care with moderate level of medical decision making at least 75 minutes	31	$5,151	$166
Return visit (30+ min)	29	$2,389	$60
Hospital discharge day management, more than 30 minutes	15	$1,601	$89

2015: 5 services

Sort by

Original Medicare services billed in 2015

Long return visit (40+ min)	97	$24,914	$89
Return visit (30+ min)	50	$7,702	$63
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	22	$7,542	$86
Initial hospital care with moderate level of medical decision making at least 75 minutes	20	$4,339	$167
Hospital discharge day management, more than 30 minutes	12	$1,073	$89

2014: 5 services

Sort by

Original Medicare services billed in 2014

Long return visit (40+ min)	46	$9,739	$91
Return visit (30+ min)	38	$6,289	$64
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	25	$5,453	$85
Initial hospital care with moderate level of medical decision making at least 75 minutes	16	$2,632	$165
Hospital discharge day management, 30 minutes or less	11	$660	$60

2013: 2 services

Sort by

Original Medicare services billed in 2013

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	17	$5,870	$83
Initial hospital care with moderate level of medical decision making at least 75 minutes	12	$1,940	$162

Medicaid work

$1,665 in 2024

Medicaid paid $1,665 for 60 billed services this clinician did in 2024, up to 15 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	60	$1,665

Sort by

Medicaid work by year

2024	60	1	15	$1,665
2019	27	1	14	$1,281
2018	141	1	15	$3,903

See the largest Medicaid services in earlier years

2019

Sort by

Largest Medicaid services in 2019

Long return visit (40+ min)	27	$1,281

2018

Sort by

Largest Medicaid services in 2018

Long return visit (40+ min)	141	$3,903

Money from drug and device companies

$19,370 in 2025

Sort by

Industry payments by year

2025	6	18	$15,690	$19,370
2024	9	18	$26,361	$27,363
2023	8	18	$29,642	$30,646
2022	6	26	$29,285	$31,011
2021	6	11	$19,059	$19,059
2020	8	31	$21,816	$24,095
2019	3	12	$12,675	$14,462

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Jazz Pharmaceuticals	Ziihera	$6,636	2 payments Meals for Ziihera · 2025-12-02 · $44 Paid to speak or teach for Ziihera · 2025-10-06 · $6,592
AstraZeneca Pharmaceuticals LP	Imfinzi	$5,717	7 payments Consulting for Imfinzi · 2025-11-03 · $2,460 Consulting for Imfinzi · 2025-09-07 · $2,055 Travel · 2025-07-23 · $422 Travel · 2025-07-23 · $10 Paid to speak or teach · 2025-07-02 · $673 Meals · 2025-05-30 · $75 Meals · 2025-05-30 · $22
AstraZeneca UK	None	$3,039	6 payments Travel · 2025-09-08 · $67 Travel · 2025-09-08 · $2,499 Travel · 2025-09-08 · $104 Meals · 2025-09-08 · $107 Travel · 2025-09-08 · $128 Meals · 2025-06-02 · $135
Guerbet	Lipiodol	$2,000	1 payment Honoraria for Lipiodol · 2025-05-30 · $2,000
E.R. Squibb & Sons L.L.C.	None	$1,910	1 payment Consulting · 2025-12-08 · $1,910
Genentech USA	None	$68	1 payment Meals · 2025-06-01 · $68

See all 18 published payments

Sort by

Every published payment

E.R. Squibb & Sons L.L.C.	Consulting · 2025-12-08	None	$1,910
Jazz Pharmaceuticals	Meals · 2025-12-02	Ziihera	$44
AstraZeneca Pharmaceuticals LP	Consulting · 2025-11-03	Imfinzi	$2,460
Jazz Pharmaceuticals	Paid to speak or teach · 2025-10-06	Ziihera	$6,592
AstraZeneca UK	Travel · 2025-09-08	None	$67
AstraZeneca UK	Travel · 2025-09-08	None	$2,499
AstraZeneca UK	Travel · 2025-09-08	None	$104
AstraZeneca UK	Meals · 2025-09-08	None	$107
AstraZeneca UK	Travel · 2025-09-08	None	$128
AstraZeneca Pharmaceuticals LP	Consulting · 2025-09-07	Imfinzi	$2,055
AstraZeneca Pharmaceuticals LP	Travel · 2025-07-23	None	$422
AstraZeneca Pharmaceuticals LP	Travel · 2025-07-23	None	$10
AstraZeneca Pharmaceuticals LP	Paid to speak or teach · 2025-07-02	None	$673
AstraZeneca UK	Meals · 2025-06-02	None	$135
Genentech USA	Meals · 2025-06-01	None	$68
AstraZeneca Pharmaceuticals LP	Meals · 2025-05-30	None	$75
AstraZeneca Pharmaceuticals LP	Meals · 2025-05-30	None	$22
Guerbet	Honoraria · 2025-05-30	Lipiodol	$2,000

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $27,363

Sort by

Payments by company in 2024

Taiho Oncology	Lytgobi	$10,000	1 payment Consulting for Lytgobi · 2024-12-17 · $10,000
AstraZeneca Pharmaceuticals LP	Imfinzi	$8,123	5 payments Consulting for Imfinzi · 2024-12-17 · $2,055 Consulting · 2024-11-16 · $343 Consulting · 2024-11-14 · $5,480 Meals for Imfinzi · 2024-02-08 · $111 Meals · 2024-01-19 · $135
Genentech	None	$2,700	3 payments Consulting · 2024-11-15 · $2,470 Travel · 2024-11-15 · $11 Meals · 2024-11-15 · $219
Merck Sharp & Dohme	Keytruda	$2,359	4 payments Consulting · 2024-03-18 · $2,135 Travel · 2024-03-04 · $150 Meals for Keytruda · 2024-02-08 · $50 Meals for Keytruda · 2024-02-08 · $24
Jazz Pharmaceuticals	None	$2,340	1 payment Paid to speak or teach · 2024-06-20 · $2,340
Boehringer Ingelheim International GmbH	None	$1,538	1 payment Paid to speak or teach · 2024-07-02 · $1,538
Array Biopharma	None	$139	1 payment Meals · 2024-01-19 · $139
TriSalus Life Sciences	Trinav Infusion System	$123	1 payment Meals for Trinav Infusion System · 2024-01-26 · $123
Genentech USA	Tecentriq	$41	1 payment Meals for Tecentriq · 2024-11-15 · $41

2023: $30,646

Sort by

Payments by company in 2023

Taiho Oncology	Lonsurf	$15,238	2 payments Consulting for Lonsurf · 2023-10-19 · $9,063 Consulting for Lonsurf · 2023-02-09 · $6,175
AstraZeneca Pharmaceuticals LP	Imfinzi	$7,797	5 payments Consulting for Imfinzi · 2023-10-24 · $4,453 Meals · 2023-10-07 · $105 Meals · 2023-10-06 · $22 Consulting · 2023-08-09 · $3,083 Meals · 2023-06-04 · $135
Exelixis	Cabometyx	$2,951	5 payments Paid to speak or teach for Cabometyx · 2023-07-27 · $2,310 Meals for Cabometyx · 2023-06-01 · $98 Travel for Cabometyx · 2023-06-01 · $448 Meals for Cabometyx · 2023-06-01 · $58 Meals for Cabometyx · 2023-06-01 · $37
Boehringer Ingelheim International GmbH	None	$2,172	2 payments Consulting · 2023-09-14 · $1,982 Paid to speak or teach · 2023-04-13 · $190
AstraZeneca UK	Imfinzi	$1,713	1 payment Consulting for Imfinzi · 2023-01-16 · $1,713
Abbvie	None	$675	1 payment Consulting · 2023-10-25 · $675
Boehringer Ingelheim Pharmaceuticals	None	$62	1 payment Meals · 2023-01-21 · $62
Genentech USA	Tecentriq	$38	1 payment Meals for Tecentriq · 2023-06-02 · $38

2022: $31,011

Sort by

Payments by company in 2022

Taiho Oncology	Inqovi	$8,542	4 payments Consulting for Inqovi · 2022-09-14 · $5,200 Consulting · 2022-01-09 · $1,625 Consulting · 2022-01-09 · $1,625 Meals · 2022-01-06 · $92
Exelixis	Cabometyx	$6,914	11 payments Paid to speak or teach for Cabometyx · 2022-11-22 · $3,300 Travel for Cabometyx · 2022-10-28 · $224 Travel for Cabometyx · 2022-10-28 · $371 Travel for Cabometyx · 2022-10-28 · $65 Travel for Cabometyx · 2022-10-28 · $45 Travel for Cabometyx · 2022-10-28 · $55 Meals for Cabometyx · 2022-10-28 · $51 Meals for Cabometyx · 2022-10-28 · $101 Travel for Cabometyx · 2022-10-26 · $65 Travel for Cabometyx · 2022-10-26 · $657 Paid to speak or teach for Cabometyx · 2022-03-10 · $1,980
Servier Pharmaceuticals	Tibsovo	$6,160	6 payments Consulting for Tibsovo · 2022-04-12 · $880 Consulting for Tibsovo · 2022-04-12 · $1,100 Consulting for Tibsovo · 2022-04-12 · $880 Consulting for Tibsovo · 2022-04-12 · $1,100 Consulting for Tibsovo · 2022-03-11 · $1,100 Consulting for Tibsovo · 2022-03-11 · $1,100
Merck Sharp & Dohme	None	$4,270	2 payments Consulting · 2022-07-13 · $2,135 Consulting · 2022-07-06 · $2,135
Boehringer Ingelheim International GmbH	None	$3,250	2 payments Consulting · 2022-04-27 · $1,625 Consulting · 2022-04-27 · $1,625
Genentech	None	$1,875	1 payment Consulting · 2022-12-14 · $1,875

2021: $19,059

Sort by

Payments by company in 2021

Sirtex Medical	Sir-Spheres Microspheres	$6,500	2 payments Consulting for Sir-Spheres Microspheres · 2021-07-01 · $3,000 Consulting for Sir-Spheres Microspheres · 2021-01-08 · $3,500
Taiho Oncology	None	$5,470	3 payments Consulting · 2021-12-06 · $2,970 Consulting · 2021-02-16 · $1,250 Consulting · 2021-02-15 · $1,250
AstraZeneca UK	Imfinzi	$4,110	3 payments Consulting · 2021-09-24 · $1,028 Consulting for Imfinzi · 2021-06-17 · $1,199 Consulting · 2021-06-17 · $1,884
Servier Pharmaceuticals	Tibsovo	$1,311	1 payment Paid to speak or teach for Tibsovo · 2021-05-20 · $1,311
Blueprint Medicines	None	$1,008	1 payment Honoraria · 2021-12-16 · $1,008
Exelixis	Cabometyx	$660	1 payment Paid to speak or teach for Cabometyx · 2021-02-02 · $660

2020: $24,095

Sort by

Payments by company in 2020

Incyte	None	$9,697	18 payments Consulting · 2020-03-19 · $2,768 Meals · 2020-01-22 · $43 Meals · 2020-01-22 · $44 Meals · 2020-01-22 · $25 Consulting · 2020-01-22 · $5,228 Travel · 2020-01-22 · $51 Travel · 2020-01-22 · $52 Meals · 2020-01-21 · $26 Travel · 2020-01-21 · $394 Meals · 2020-01-16 · $5 Meals · 2020-01-16 · $38 Travel · 2020-01-16 · $48 Travel · 2020-01-16 · $48 Travel · 2020-01-15 · $572 Travel · 2020-01-15 · $208 Travel · 2020-01-15 · $56 Meals · 2020-01-15 · $56 Travel · 2020-01-15 · $35
Sirtex Medical	Sir-Spheres Microspheres	$6,663	5 payments Consulting for Sir-Spheres Microspheres · 2020-12-18 · $3,500 Consulting for Sir-Spheres Microspheres · 2020-08-20 · $500 Honoraria for Sir-Spheres Microspheres · 2020-02-05 · $2,200 Meals for Sir-Spheres Microspheres · 2020-01-30 · $364 Meals for Sir-Spheres Microspheres · 2020-01-11 · $99
AstraZeneca UK	None	$4,453	2 payments Consulting · 2020-10-09 · $2,740 Consulting · 2020-02-28 · $1,713
Agios Pharmaceuticals	Tibsovo	$1,427	2 payments Consulting for Tibsovo · 2020-03-25 · $1,408 Meals for Tibsovo · 2020-02-13 · $19
Genentech USA	Tecentriq	$1,100	1 payment Consulting for Tecentriq · 2020-11-30 · $1,100
Exelixis	Cabometyx	$660	1 payment Paid to speak or teach for Cabometyx · 2020-11-19 · $660
Taiho Oncology	Lonsurf	$61	1 payment Meals for Lonsurf · 2020-01-24 · $61
Eisai	None	$35	1 payment Meals · 2020-02-28 · $35

2019: $14,462

Sort by

Payments by company in 2019

Taiho Oncology	Lonsurf	$10,278	5 payments Consulting · 2019-12-12 · $1,875 Consulting for Lonsurf · 2019-08-06 · $7,500 Travel for Lonsurf · 2019-08-06 · $194 Meals for Lonsurf · 2019-08-06 · $17 Travel for Lonsurf · 2019-07-22 · $693
Agios Pharmaceuticals	Tibsovo	$4,084	6 payments Honoraria for Tibsovo · 2019-11-15 · $3,300 Meals for Tibsovo · 2019-11-15 · $116 Travel for Tibsovo · 2019-11-14 · $218 Travel for Tibsovo · 2019-11-14 · $257 Travel for Tibsovo · 2019-11-14 · $112 Meals for Tibsovo · 2019-11-14 · $81
Sirtex Medical	Sir-Spheres Microspheres	$99	1 payment Meals for Sir-Spheres Microspheres · 2019-03-25 · $99

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

AstraZeneca Pharmaceuticals LP · A Phase III,Randomized,Double Blind,Placebo Controlled,Multicenter,Global Study of Rilvegostomig in Combination With Chemotherapy As Adjuvant Treatment in Adult Participants After Resection of Biliary Tract Cancer With Curative Intent Artemide Biliary01 · 2025	Their institution	$609,501
Genentech, Inc. · Atezolizumab and Bevacizumab Tiragolumab in 1l Unresectable Hcc Pts · 2025	Their institution	$569,281
Incyte Corporation · A Phase 1, Open-Label, Multicenter Study of Incb161734 in Participants With Advanced Or Metastatic Solid Tumors With Kras G12d Mutation · 2025	Their institution	$487,017
Eli Lilly and Company · A Phase 1 Study of Ly3410738 Administered To Patients With Advanced Solid Tumors With Idh1 Or Idh2 Mutations · 2022	Their institution	$363,146
Taiho Oncology, Inc. · 2019	Their institution	$354,274
AstraZeneca Pharmaceuticals LP · A Phase II Open-Label Multi-Centre Study To Evaluate Safety Tolerability Efficacy Pk and Immunogenicity of Azd0901 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 182 · 2025	Their institution	$329,057
BeiGene, Ltd. · A Randomized, Open-Label, Multicenter Phase 3 Study To Compare the Efficacy and Safety of Bgb-A317 Versus Sorafenib As First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma · 2020	Their institution	$283,861
Taiho Oncology, Inc. · 2020	Their institution	$248,392
Genentech, Inc. · Atezolizumab and Bevacizumab Tiragolumab in 1l Unresectable Hcc Pts · 2024	Their institution	$216,640
Merck Sharp & Dohme Corporation · A Phase 3 Multicenter, Randomized, Double-Blinded, Active-Controlled, Clinical Study To Evaluate the Safety and Efficacy of Lenvatinib E7080,Mk-7902 in Combination With Pembrolizumab Mk-3475 Versus Lenvatinib in First-Line Therapy of Participants With Advanced Hepatocellular Carcinoma Leap-002 · 2020	Their institution	$184,634
Eli Lilly and Company · Tbc Ly3802 Study · 2021	Their institution	$184,429
Taiho Oncology, Inc. · Tpu-Tas-120-101 · 2019	Their institution	$163,223
Merck Sharp & Dohme Corporation · A Phase 3 Double-Blinded, Two-Arm Study To Evaluate the Safety and Efficacy of Pembrolizumab Mk-3475 Versus Placebo As Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection Or Local Ablation Keynote-937 · 2020	Their institution	$142,011
Bayer HealthCare Pharmaceuticals Inc. · Regorafenib Combined With Pembrolizumab in Hcc After Io · 2022	Their institution	$135,092
MACROGENICS, INC. · A Study of Mgd013 in Patients With Unresectable Or Metastatic Neoplasms · 2021	Their institution	$128,324
Taiho Oncology, Inc. · 2021	Their institution	$67,481
AstraZeneca Pharmaceuticals LP · A Phase III,Randomised,Open Label,Sponsor Blinded,Multicentre Study of Rilvegostomig in Combination With Bevacizumab With Or Without Tremelimumab As First Line Treatment in Patients With Advanced Hepatocellular Carcinoma · 2025	Their institution	$61,653
Taiho Oncology, Inc. · An Open-Label Expanded Access Program of Futibatinib (Tas-120) in Patients With Advanced Cholangiocarcinoma Harboring Fgfr2 Gene Rearrangements · 2021	Their institution	$60,000
Merck Sharp & Dohme Corporation · A Phase 3 Double-Blinded, Two-Arm Study To Evaluate the Safety and Efficacy of Pembrolizumab Mk-3475 Versus Placebo As Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection Or Local Ablation Keynote-937 · 2021	Their institution	$59,385
Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic Or Surgically Unresectable Solid Tumor Malignancies Harboring Activating Fgfr Mutations Or Translocations (Fight-207) · 2021	Their institution	$45,957
Bayer HealthCare Pharmaceuticals Inc. · An Open-Label Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced Or Metastatic Hepatocellular Carcinoma (Hcc) After Pd-1/Pd-L1 Immune Checkpoint Inhibitors · 2021	Their institution	$41,265
Merck Sharp & Dohme Corporation · A Phase 3 Multicenter, Randomized, Double-Blinded, Active-Controlled, Clinical Study To Evaluate the Safety and Efficacy of Lenvatinib E7080,Mk-7902 in Combination With Pembrolizumab Mk-3475 Versus Lenvatinib in First-Line Therapy of Participants With Advanced Hepatocellular Carcinoma Leap-002 · 2021	Their institution	$40,090
Agios Pharmaceuticals, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Ag-120 in Previously-Treated Subjects With Nonresectable Or Metastatic Cholangiocarcinoma With An Idh1 Mutation · 2020	Their institution	$38,047
Eli Lilly and Company · Tbc Ly3802 Study · 2020	Their institution	$36,450
MACROGENICS, INC. · A Study of Mgd013 in Patients With Unresectable Or Metastatic Neoplasms · 2024	Their institution	$34,251
Exelixis Inc. · A Dose-Escalation and Expansion Study of the Safety and Efficacy of Xl092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced Or Metastatic Solid Tumors · 2024	Their institution	$33,455
Merck Sharp & Dohme Corporation · A Phase 3 Multicenter, Randomized, Double-Blinded, Active-Controlled, Clinical Study To Evaluate the Safety and Efficacy of Lenvatinib E7080,Mk-7902 in Combination With Pembrolizumab Mk-3475 Versus Lenvatinib in First-Line Therapy of Participants With Advanced Hepatocellular Carcinoma Leap-002 · 2019	Their institution	$29,359
Exelixis Inc. · A Dose-Escalation and Expansion Study of the Safety and Efficacy of Xl092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced Or Metastatic Solid Tumors · 2025	Their institution	$28,008
AstraZeneca Pharmaceuticals LP · A Modular Phase I Iia Open-Label Multi-Centre Study To Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of Azd0022 Monotherapy and in Combination With Anti-Cancer Agents in Participants With Tumours Harbouring A Krasg12d Mutation · 2025	Their institution	$27,610
Genentech, Inc. · A Phase II Study of Atezolizumab With Or Without Bevacizumab in Patients With Hcc · 2024	Their institution	$27,300
QED Therapeutics, Inc. · 2021	Their institution	$20,949
Eli Lilly and Company · Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care -Bsc- Versus Placebo and Bsc As Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein -Afp- Following First Line Therapy With Sorafenib · 2021	Their institution	$20,922
Genentech, Inc. · A Phase II Study of Atezolizumab With Or Without Bevacizumab in Patients With Hcc · 2025	Their institution	$20,486
MACROGENICS, INC. · A Study of Mgd013 in Patients With Unresectable Or Metastatic Neoplasms · 2022	Their institution	$17,500
Blueprint Medicines Corporation · A Phase 1 Study of Fisogatinib (Blu-554) in Patients With Hepatocellular Carcinoma · 2021	Their institution	$16,500
Blueprint Medicines Corporation · 2020	Their institution	$13,178
QED Therapeutics, Inc. · Qbgj398-301 · 2022	Their institution	$12,942
TAIHO ONCOLOGY, INC. · An Open-Label Expanded Access Program of Futibatinib (Tas-120) in Patients With Advanced Cholangiocarcinoma Harboring Fgfr2 Gene Rearrangements · 2022	Their institution	$11,560
Eli Lilly and Company · Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care -Bsc- Versus Placebo and Bsc As Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein -Afp- Following First Line Therapy With Sorafenib · 2020	Their institution	$10,285
E.R. Squibb & Sons, L.L.C. · Ph I Hepatocellular Ca210-005 · 2019	Their institution	$10,212
Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic Or Surgically Unresectable Solid Tumor Malignancies Harboring Activating Fgfr Mutations Or Translocations (Fight-207) · 2022	Their institution	$9,947
QED Therapeutics, Inc. · Truseltiq · 2022	Their institution	$8,600
MacroGenics, Inc. · A Study of Mgd013 in Patients With Unresectable Or Metastatic Neoplasms · 2021	This clinician	$8,277
Eisai Inc. · A Multicentre, Observational, Phase 4 Study To Evaluate the Safety and Tolerability of Lenvatinib in Patients With Advanced Or Unresectable Hepatocellular Carcinoma (Stellar) · 2022	Their institution	$7,500
Blueprint Medicines Corporation · A Phase 1 Study of Fisogatinib (Blu-554) in Patients With Hepatocellular Carcinoma · 2022	Their institution	$7,326
Agios Pharmaceuticals, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Ag-120 in Previously-Treated Subjects With Nonresectable Or Metastatic Cholangiocarcinoma With An Idh1 Mutation · 2021	Their institution	$6,538
Bayer Healthcare Pharmaceuticals Inc. · Regorafenib Combined With Pembrolizumab in Hcc After Io · 2023	Their institution	$6,456
Eli Lilly and Company · Randomized Double-Blind Placebo-Controlled Phase 3 Study of Ramucirumab and Best Supportive Care -Bsc- Versus Placebo and Bsc As Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein -Afp- Following First Line Therapy With Sorafenib · 2023	Their institution	$6,000
Servier BioInnovation · Study of Ag-120 in Previously Treated Advanced Cholangiocarcinoma With Idh1 Mutations (Claridhy) (Claridhy) · 2023	Their institution	$5,720
MACROGENICS, INC. · A Study of Mgd013 in Patients With Unresectable Or Metastatic Neoplasms · 2023	Their institution	$4,500
Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic Or Surgically Unresectable Solid Tumor Malignancies Harboring Activating Fgfr Mutations Or Translocations (Fight-207) · 2023	Their institution	$3,142
Bayer Healthcare Pharmaceuticals Inc. · Bay 734506, An Open-Label Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced Or Metastatic Hepatocellular Carcinoma (Hcc) After Pd1/Pd-L1 Immune Checkpoint Inhibitor · 2024	Their institution	$3,000
Agios Pharmaceuticals, Inc. · Study of Ag-120 in Previously Treated Advanced Cholangiocarcinoma With Idh1 Mutations Claridhy · 2019	Their institution	$2,874
Merck Sharp & Dohme Corporation · A Phase 3 Double-Blinded, Two-Arm Study To Evaluate the Safety and Efficacy of Pembrolizumab Mk-3475 Versus Placebo As Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection Or Local Ablation Keynote-937 · 2019	Their institution	$2,258
BeiGene, Ltd. · Rationale-301: A Randomized, Open-Label, Multicenter Phase 3 Study To Compare the Efficacy and Safety of Bgb-A317 Versus Sorafenib As First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma · 2021	Their institution	$2,147
Eli Lilly and Company · Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care -Bsc- Versus Placebo and Bsc As Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein -Afp- Following First Line Therapy With Sorafenib · 2022	Their institution	$2,000
Servier Pharmaceuticals LLC · Study of Ag-120 in Previously Treated Advanced Cholangiocarcinoma With Idh1 Mutations (Claridhy) (Claridhy) · 2021	Their institution	$1,628
Eli Lilly and Company · Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care -Bsc- Versus Placebo and Bsc As Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein -Afp- Following First Line Therapy With Sorafenib · 2021	This clinician	$586

Professional record

NPI: 1720287055
Licence: CA C184275, MA 253436California C184275: Current · expires 2027-02-28
Trained: Harvard Medical School, 2007
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Female

More record details

Sole proprietor: No
Taxonomy: Medical oncology (207RX0202X); Federal specialty code 207RH0003X (207RH0003X)
Mailing address: 300 Pasteur Dr, Stanford, CA, 94305
NPI first listed: 2007-07-17
NPI last updated: 2024-04-26
NPI record certified: 2024-04-26

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 55 Fruit St, Boston, MA, 02114